Bioprocessing Europe
This Summit brings together 750+ upstream, downstream, bioproduction, analytical and formulation professionals to advance the manufacture, quality and control of biological and genetic therapies.
This Summit brings together 750+ upstream, downstream, bioproduction, analytical and formulation professionals to advance the manufacture, quality and control of biological and genetic therapies.
Kathryn Golden, SVP Technical Operations & Cell Manufacturing will be speaking at this event.
The 2024 Bioprocessing Summit Europe continues the tradition of delivering two deep-dive panels in the Cell Therapy CMC and Manufacturing track, focusing on the unique challenges and shared opportunities in allogeneic and autologous production and manufacturing. Kathryn Golden will be an expert panellist for both of the discussions:
The Role of Decentralised vs. Centralised Manufacturing
Moderated by Angela Osborne, PhD, CEO & Founder, eXmoor Pharma Concepts Ltd.
The role of local academic/hospital GMP centres which got the industry started, continues to be important but alternative solutions are needed for therapies to reach all patients who need them once they are approved.
Panel members:
- Lee Buckler, Senior Vice President, Advanced Therapies, Blood Centers of America Vered Caplan, CEO, Octomera and Orgenesis
- Christopher Baldwin, Vice President, Manufacturing and Supply, Resolution Therapeutics
- Kathryn Golden, SVP Technical Operations & Cell Manufacturing, Tech Operations & Cell Mfg, bit.bio
- Stephen Judd, Process Subject Matter Expert, Biologics, Cell and Gene Therapy, DPS Group Global
ISCT PANEL DISCUSSION: Allogeneic Productivity and Technologies: Unique Challenges - Common Threads
Moderated by Anthony Ting, Chief Scientific Officer, Kiji Therapeutics, Chief Commercialization Officer and Board Member, ISCT
This panel representing biopharma and technology providers will deep-dive and discuss challenges and solutions to overcome allogeneic development and manufacturing challenges, including: (1) batch logistic strategies; (2)improving operator skill levels; (3) design facility footprint; (4) addressing operational constraints; (5) process optimisation; (6) increasing batch potency; (7) technology gaps; and (8) implementing AI, ML, and automation.
Panel members:
- Cenk Sumen, PhD, Advisor, MaxCyte Inc.; PDM Committee Member, ISCT
- Kathryn Golden, SVP Technical Operations & Cell Manufacturing, Tech Operations & Cell Mfg, bit.bio
- Julie G. Allickson, PhD, Michael S. and Mary Sue Shannon Family Director, Mayo Clinic Center for Regenerative Medicine, Member, ISCT
- Stephan Croft, Senior Principal, Head of Quality, Dark Horse Consulting Group